Live Breaking News & Updates on Astrazeneca Calquence
Stay updated with breaking news from Astrazeneca calquence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
against ibrutinib in chronic lymphocytic leukaemia
Superior safety on key secondary endpoint of atrial fibrillation Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca s Calquence (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukaemia (CLL) compared to ibrutinib.
The trial also met a key secondary endpoint for safety, showing patients treated with Calquence had statistically significantly lower incidence of atrial fibrillation compared to patients treated with ibrutinib. Atrial fibrillation is an irregular heart rate that can increase the risk of stroke, heart failure and other heart-related complications . 1 Further hierarchical testing revealed no difference for Grade 3 or higher infections or Richter s transformation. There was a descri ....